What Insulet does

Insulet Corporation (NASDAQ: PODD) is a Massachusetts-headquartered medical device company that develops, manufactures, and sells the Omnipod line of tubeless, wearable insulin delivery systems for people with insulin-dependent diabetes. Founded in 2000 by John Brooks after his son's type 1 diabetes diagnosis, Insulet serves more than 600,000 global customers across 25 countries, including approximately 100,000 children, and reported $2.7B in 2025 revenue with Q1 2026 revenue of $761.7M growing 33.9% year-over-year. The company employs roughly 2,900 people globally and operates as an independent publicly traded entity with no parent company, led by CEO Ashley McEvoy.

The core technology is the Omnipod platform: a disposable, waterproof (IP28 rating for up to 25 feet for 60 minutes) Pod that delivers continuous insulin for up to 72 hours without tubing, paired with proprietary automated insulin delivery (AID) algorithms. The flagship Omnipod 5 system integrates with continuous glucose monitors (CGMs) including Abbott's FreeStyle Libre 3 Plus and Dexcom sensors, offers six target glucose options (100-150 mg/dL), and is smartphone-controlled. The portfolio spans three shipping generations (Eros, DASH, Omnipod 5) plus two pipeline products—Omnipod 6, with STRIVE pivotal trial data showing 54% time in tight range and a targeted 2027 launch, and a fully closed-loop system for type 2 diabetes with 2028 launch intent. Manufacturing is performed at highly automated facilities in Acton, Massachusetts and Johor Bahru, Malaysia, with the company holding an extensive patent portfolio (23+ Omnipod 5 patents, multiple design patents) and trademarks protecting the Omnipod, Podder, and Toby the Turtle brands.

Insulet's business model is dominated by recurring consumables revenue from the Pod replacement cycle of its 600,000+ installed base; the reusable controller represents a one-time hardware purchase. The company employs a multi-channel go-to-market combining direct-to-consumer engagement (website, customer care, financial assistance programs), a direct field sales force targeting endocrinologists and healthcare providers, pharmacy distribution, and international distributors. Omnipod 5 is the #1 requested and prescribed AID system in the U.S. per the dQ&A HCP AID Algorithm Study (2025), and the company generated 71% gross margins in 2025 with full-year 2026 revenue guidance raised to 21-23% growth.

Name

Insulet

Legal name

Insulet Corporation

Website

https://insulet.com

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Insulet Corporation (NASDAQ: PODD) is a medical device company that develops the Omnipod line of tubeless, wearable automated insulin delivery systems, serving more than 600,000 people with insulin-dependent diabetes across 25 countries via a recurring consumables model.

Ownership category

akta.pro rank

Product category

Insulin Delivery Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)

akta.pro secondary industry

Patch Pumps & Wearable Insulin Delivery (HLAHAHAC)

Keywords

• Insulin delivery systems
• Automated insulin delivery
• Tubeless insulin pumps
• Diabetes management devices
• Continuous glucose monitoring

Headquarters

HQ city

Acton

HQ country

United States

HQ region

North America

Offices13 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Marketing or Sales, Personnel, Supply Chain

Revenue model

1. Omnipod Pod Consumables (Recurring): The primary revenue driver is the recurring consumables model centered on Pod replacements. Each Pod provides up to 72 hours of insulin delivery before requiring replacement, creating a recurring revenue stream from the installed base of 600K+ global customers. The recurring consumables cycle drives growth across both U.S. and international markets.
2. Omnipod Insulin Management System Hardware: Initial system sales include the reusable controller/device along with starter Pod supplies. While the controller is a one-time purchase, the ongoing Pod consumables represent the primary revenue stream.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Insulet develops, manufactures, and sells the Omnipod line of tubeless, wearable, waterproof insulin delivery systems for people with insulin-dependent diabetes. The company offers the Omnipod 5 Automated Insulin Delivery (AID) System as its flagship product, integrating with continuous glucose monitors (CGMs) to automatically adjust insulin dosing via a smartphone app. Revenue is driven primarily by recurring sales of disposable Pods (each providing up to 72 hours of insulin delivery), supported by a reusable controller and cloud-connected data management tools.

Product overview

Insulet is a medical device company that develops, manufactures, and sells the Omnipod line of tubeless, wearable insulin delivery systems. The product portfolio consists of three generations of the core Omnipod Insulin Management System (Eros, DASH, and 5), along with two pipeline products in development (Omnipod 6 and a fully closed-loop system for type 2 diabetes). The Omnipod 5 AID system is the current flagship product providing automated insulin delivery with CGM integration, while the Omnipod DASH offers a touchscreen interface and Eros represents the legacy system. All products share the distinctive tubeless, waterproof Pod design providing up to 72 hours of insulin delivery. The company is expanding from primarily type 1 diabetes into the larger type 2 diabetes market through its fully closed-loop system development.

Differentiator

Problem solved

Functional benefit

Brands

• Omnipod 5: Automated Insulin Delivery System - tubeless, wearable, cloud-connected insulin pump system controlled by smartphone, approved for patients ages 2 and up with type 1 and type 2 diabetes
• Omnipod DASH
• Omnipod Eros
• Omnipod 6
• Fully Closed-Loop System
• Omnipod Discover
• My Omnipod

Quantifiable outcome

• Time in tight range improved from 47% to 54% with Omnipod 6 vs Omnipod 5 in Type 1 diabetes patients
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability3 records

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Abbott LaboratoriescoreTechnology or IntegrationAbbott's FreeStyle Libre 3 Plus CGM sensor integration with Omnipod 5 provides users with additional sensor options. This integration represents a key competitive differentiator, expanding compatibility beyond Dexcom CGM systems.
• Healthcare Authorities (International)coreChannel Partner/ Reseller/ DistributorPartnerships with health authorities internationally to drive equitable access to diabetes management technology. Working with governments, health technology assessment bodies, and payors to evaluate Omnipod technology.
• Industry Associations and Medical Professional OrganizationsminorStrategic or Co-development PartnerStrategic partnerships with industry associations, medical professional organizations, and consumer advocacy groups to broaden diabetes care efforts and co-create programs meeting community needs.
• Nonprofit Diabetes OrganizationsminorGTM or Marketing PartnerPartnerships with nonprofit organizations providing community-centered care through resources, tools, and services. Focus on reducing health barriers and disparities in underserved communities living with diabetes.
• Responsible Business Alliance (RBA)minorOthersMember of RBA, the world's largest industry coalition dedicated to corporate social responsibility in global supply chains. Adopted RBA Code of Conduct as Insulet Supplier Code of Conduct.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Tandem Diabetes Care: Tandem's t:slim X2 with Control-IQ is a direct AID competitor to Omnipod 5, serving the same Type 1 diabetes patient population with automated insulin delivery integrated to Dexcom CGMs. Closest comparable in product category, business model, and target prescriber base.
• EOFlow: EOFlow's EOPatch is a tubeless, wearable patch pump that most closely resembles the Omnipod form factor. Direct patch-pump competitor with overlapping design philosophy and target patient population; subject of prior trade-secret litigation with Insulet.

Broad incumbents

• Medtronic Diabetes: Medtronic's MiniMed 780G is the dominant incumbent AID system globally with established payor contracts and HCP relationships. Competes directly with Omnipod 5 in hybrid closed-loop insulin delivery but with a tubed form factor and broader diabetes portfolio (sensors, pumps, services).
• Roche Diabetes Care: Roche's Accu-Chek portfolio (Smart insulin pen, Insight pump, CGM via Roche/MediTuner) competes broadly in diabetes management with global reach. Larger and more diversified than Insulet but with less algorithmic and patch-pump specialization in AID.

Emerging players

• Beta Bionics: Beta Bionics' iLet bionic pancreas is an emerging AID system approved for both Type 1 and Type 2 diabetes, competing directly with Omnipod 5's expanding indications. Smaller commercial scale but credible algorithmic challenger with growing real-world evidence.
• Diabeloop: Diabeloop develops closed-loop insulin delivery algorithms (DBLG1) integrated with multiple pumps including patch form factors, with growing focus on Type 2 diabetes. Direct algorithmic and product overlap with Omnipod 5/6 and a credible challenger in the European T2D expansion opportunity.
• Bigfoot Biomedical: Bigfoot's Unity system offers a connected insulin pen ecosystem with Type 1 and Type 2 indications, addressing adjacent diabetes management use cases. Earlier-stage commercialization but overlaps with Insulet's underserved community and T2D expansion strategies.

Others

• Dexcom: Dexcom's G6/G7 CGM is the historical primary sensor integrated with Omnipod 5 and Control-IQ. Functions as both a key supplier/partner and adjacent competitor as CGM-algorithm stacks increasingly define AID outcomes — vertical integration could pressure Insulet long term.
• Abbott Diabetes Care: Abbott's FreeStyle Libre 2/3/3 Plus CGM is now integrated with Omnipod 5 (FDA-cleared June 2026). Strategic sensor partner and indirect competitive dynamic as Abbott expands its own diabetes ecosystem (Libre sensors, Biowearable platform).

Regional players

• Ypsomed: Ypsomed's mylife Loop with YpsoPump and CamAPS FX algorithm is a meaningful European AID competitor with tubed and emerging patch offerings. Comparable product/market approach but primarily serves EU/UK markets versus Insulet's U.S.-centric installed base.

Market position

Strengths5 records

Weaknesses6 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/insulet-corporation
• Xx.com/myomnipod

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds7 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Insulet